A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation
A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation
The study will assess the long-term safety of the fixed combination product QVA149 versus placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitation.
Inclusion criteria:
Exclusion criteria:
Buenos Aires, Buenos Aires 1425, Argentina
Buenos Aires, Buenos Aires B1842DID, Argentina
Caba, Buenos Aires 1028, Argentina
Caba, Buenos Aires C1113AAC, Argentina
Caba, Buenos Aires C1122AAK, Argentina
Caba, Buenos Aires C1180AAX, Argentina
Caba, Buenos Aires C1425AUA, Argentina
Bogota, Cundinamarca, Colombia
Hyderabad, Andhra Pradesh 500004, India
Nagpur - Maharashtra, India 440012, India
N.Novgorod, 603126, Russia
Pendik / Istanbul, Turkey 1330, Turkey (Türkiye)
Yenisehir/Izmir, 35110, Turkey (Türkiye)
Cheshire, CW1 4QJ, United Kingdom
Merseyside, CH49 5PE, United Kingdom